EASL guidance recommends resmetirom or semaglutide for non-cirrhotic MASH with fibrosis stages 2-3
MASH pharmacotherapy decision path
Follow the path from top to bottom. Text in quotation marks is the guidance’s own wording.
this joint EASL-EASD-EASO guidance provides updated recommendations for the use of resmetirom (80mg/100mg po) and semaglutide (2.4 mg sc weekly) in MASH
Step 1 · Who qualifies for treatment
Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimized comorbidity management.
adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy)
Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimized comorbidity management.
VCTE 10-20 kPa, MRE 3.1-5.0 kPa, or ELF 9.8-11.3
in which pharmacotherapy may be considered
Step 2 · How to choose the agent
Therapy selection should be individualized according to preferences, potential risks, and cardio-renal-metabolic profile, including presence of obesity, type 2 diabetes (T2D), cardiovascular, and chronic kidney disease.
adults with obesity or T2D as well as with established cardiovascular (CV) disease or high CV risk
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), may be preferred in adults with obesity or T2D as well as with established cardiovascular (CV) disease or high CV risk because of its cardiometabolic benefits
individuals without obesity or those already receiving or intolerant to GLP-1RAs
resmetirom may be prioritized in individuals without obesity or those already receiving or intolerant to GLP-1RAs
Step 3 · Monitoring during therapy
Additional recommendations include structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria.
structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria
Step 4 · Cirrhosis exclusion
adults with MASH cirrhosis
resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits
The publication
A joint EASL-EASD-EASO guideline recommends pharmacotherapy with resmetirom or semaglutide for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages 2-3. The guidance advises using non-invasive tests to identify high-risk patients and individualizing therapy based on cardiometabolic profiles.
Who the findings apply to
The recommendation applies to adults with non-cirrhotic MASH and fibrosis stages 2-3, identified by non-invasive tests or biopsy.
Non-invasive tests for hepatic fibrosis, such as vibration-controlled transient elastography, magnetic resonance elastography, or enhanced liver fibrosis score, can replace liver biopsy to identify high risk for major adverse liver-related outcomes.
Specific thresholds for high risk include vibration-controlled transient elastography of 10-20 kPa, magnetic resonance elastography of 3.1-5.0 kPa, or enhanced liver fibrosis score of 9.8-11.3.
In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment until further data establish liver-related benefits.
Why this matters
Adults with MASH are at risk for major adverse liver-related outcomes, including cirrhosis, cancer, and liver transplantation. This guidance provides updated recommendations for treatment candidate selection, initiation, monitoring, and discontinuation following regulatory approval of these agents. It emphasizes that therapy selection should be individualized according to preferences, potential risks, and the presence of obesity, type 2 diabetes, cardiovascular, or chronic kidney disease.
What the study found
The guidance recommends pharmacotherapy for adults with non-cirrhotic MASH and fibrosis stages 2-3 alongside structured lifestyle intervention and optimized comorbidity management.
Semaglutide, a glucagon-like peptide-1 receptor agonist, may be preferred in adults with obesity or type 2 diabetes, as well as those with established cardiovascular disease or high cardiovascular risk, because of its cardiometabolic benefits.
Resmetirom may be prioritized in individuals without obesity or those already receiving or intolerant to glucagon-like peptide-1 receptor agonists.
Recommended doses include resmetirom 80mg or 100mg orally and semaglutide 2.4 mg subcutaneously weekly.
What the result does not establish
Ongoing studies are evaluating the long-term effectiveness of both agents to reduce major adverse liver-related outcomes.
In adults with MASH cirrhosis, the agents should not be used as MASH-targeted treatment until further data establish liver-related benefits.
Additional recommendations include structured safety and efficacy monitoring, such as nutritional and sarcopenia assessment during semaglutide use or the use of fibrosis non-invasive tests for longitudinal response criteria.
Authors’ conclusion
“Ongoing studies are evaluating long-term effectiveness of both agents to reduce MALO. In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits.”
Study and sources
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
Guidelines & recommendations · Journal of hepatology · 2026-12-01
Sources and limitations
- PubMed record PMID 42805503 (PubMed / NLM · 2026-09-29)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


